ABOUT GENESIS XBT
Genesis XBT is a global summit that brings together biotech founders, scientists, investors, policy leaders, and innovators shaping the future of life sciences.
Originally known for its leading crypto and frontier-tech conferences, Genesis XBT has expanded into biotechnology, a sector transforming healthcare, longevity, and the future of human progress. Our mission is to create a space where breakthrough science meets capital, industry expertise, and visionary thinking.
The summit gathers world-class researchers, venture capital firms, biotech executives, family offices, and institutional leaders. Through high-level discussions, curated networking, and deal-flow opportunities, Genesis XBT enables meaningful connections that accelerate scientific and entrepreneurial impact.
The Longevity Revolution: Targeting the Biology of Aging to Avert the Global Age Crisis
The United Nations World Population Prospects 2024 revision reveals that the number of people aged 65 and over now exceeds, for the first time in human history, the number of children under the age of 5. By 2050, the number of persons aged 65+ is projected to reach 1.6 billion, more than double the expected number of children under 5 (approximately 650 million) and roughly equal to the projected number of children under 12.
This unprecedented demographic inversion represents one of the most profound socioeconomic and medical challenges of the 21st century. Age-related diseases: cardiovascular disease, cancer, neurodegenerative disorders, osteoarthritis, immunosenescence, and metabolic dysfunction, currently account for more than 70% of global mortality and over 50% of disability-adjusted life years in adults over 60. The resulting strain on healthcare systems, pension schemes, and workforce productivity is already measurable: in OECD countries, public spending on long-term care is projected to rise from 1.7% of GDP today to between 2.6% and 3.8% by 2060, even under conservative scenarios.
Addressing this challenge requires nothing less than a fundamental reorientation of biomedical research and clinical practice toward the biology of aging itself. Recent scientific advances, ranging from cellular reprogramming and senolytic therapies to epigenetic rejuvenation, NAD+ restoration, and targeted clearance of amyloid and tau aggregates, demonstrate that the underlying processes of aging are not immutable and can be modulated therapeutically.
This year’s program brings together the world’s foremost authorities in geroscience, longevity biotechnology, and translational aging research. They will present the latest breakthrough data from human trials, large-scale cohort studies, and novel interventional platforms designed to delay, prevent, or reverse multiple age-associated pathologies simultaneously. The shared objective is unambiguous: to compress morbidity, extend healthspan, and enable the majority of individuals born today to reach their tenth decade in robust physiological condition, thereby transforming an impending demographic crisis into an era of extended human potential.
Speaker Application
Exceptional speakers are central to the Genesis XBT experience. Attendees come to hear from the individuals who are driving scientific, technological, and societal progress. We curate thought-leaders, researchers, founders, policymakers, and industry executives who are shaping the future of biotechnology, longevity science, and frontier innovation. Their insights, research, and expertise set the tone for the discussions that define our summit.
If you are interested in becoming a speaker at an upcoming Genesis XBT event, please contact us at speak@genesisxbt.com Include your professional background, areas of expertise, proposed topics, and preferred speaking format.
KEY THEMES
LONGEVITY SCIENCE & GEROSCIENCE
Mechanisms of aging. Cellular senescence, proteostasis, telomeres, mitochondrial function.
Translating aging biology into therapeutic targets.
AGE-ASSOCIATED DISEASES & THERAPEUTIC INTERVENTIONS
Cardiovascular aging, neurodegeneration, metabolic disorders, immune aging (immunosenescence).
Opportunities for prevention, delay, and reversal.
AI-DRIVEN DRUG DISCOVERY & COMPUTATIONAL BIOLOGY
Machine learning for target identification.
Generative models for molecule design.
Predictive biomarkers and biological age estimation.
CELL & GENE THERAPIES
Gene editing (CRISPR, base/prime editing).
Cellular rejuvenation approaches.
Regenerative medicine for age-related decline.
BIOMARKERS OF AGING & DIAGNOSTICS
Epigenetic clocks, proteomic & metabolomic biomarkers.
Real-time monitoring of biological age.
Validation, standardization, and regulatory pathways.
HEALTHSPAN, LIFESTYLE INTERVENTIONS & PREVENTIVE MEDICINE
Nutrition, exercise physiology, microbiome research.
Clinical evidence on existing and emerging interventions.
Metabolic and hormonal optimization.
CAPITAL MARKETS & BIOTECH INVESTING
Funding longevity biotech.
VC, family offices, institutional capital in life sciences.
Valuations, risk, deal-flow, and commercialization strategies.
CLINICAL TRIALS, REGULATION & POLICY
FDA and EMA perspectives.
Designing trials for aging and age-related conditions.
Ethical and regulatory frameworks for novel therapies.
DATA PRIVACY, BIOSECURITY & SAFETY FRAMEWORKS
AI-risk in biology.
Safe deployment of synthetic biology tools.
Protecting genomic and biomedical data.
EMERGING AREAS: SYNTHETIC BIOLOGY, NANOTECH, REGENERATIVE SYSTEMS
Programmable biology.
Tissue engineering and organ regeneration.
Nano-delivery systems for precise therapeutics.
COMPARATIVE LONGEVITY & ANIMAL MODELS OF AGING
Exceptional longevity in animals: naked mole-rats, bats, bowhead whales, tortoises.
Studying natural mechanisms of disease resistance, DNA repair, and stress tolerance.
Translational insights from animal models to human aging interventions.
EXTREME LONGEVITY & THE POSSIBILITY OF RADICAL LIFE EXTENSION
Exploring biological, technological, and ethical boundaries of extending human lifespan beyond current limits.
Cross-disciplinary perspectives from biotech, AI, regenerative medicine, and philosophy.
PAST SPEAKERS
JOIN INDUSTRY LEADERS
WATCH & EDUCATE YOURSELF
Keynote: The Evolution of Tether
Speaker: Paolo Ardoino, CEO at Tether, CTO at Bitfinex
Tether tokens are the most widely adopted stablecoins. Tether (USDT) is the largest stablecoin by market capitalization. Stablecoin issuer Tether reported a 'record-breaking' $2.85 billion of profits in Q4 2023 as its flagship token USDT neared a $100 billion market capitalization.
The President of Palau, Surangel Whipps, Jr., talks about Palau tech initiatives. After the pandemic, Palau started actively diversifying its economy, exploring applications of blockchain technology. Palau is the first sovereign nation in the world to authorize a blockchain-native digital residency program. Taras Marchuk, Managing partner at Astra Capital, hosted a fireside chat with Surangel Whipps, Jr. Enjoy a short version of their conversation.
Panel discussion: How institutional adoption is changing the future of digital assets
Moderator: Jorge Carrasco, Managing Director, Blockchain and Digital Assets, FTI Consulting; Speakers: Luuk Strijers, CCO, Deribit;
Payal Shah, Director of Equity & Cryptocurrency Product Development, CME Group;
Jihane Hajjaji, Sales Executive, MENA, Blockdaemon.
Presentation: How can Web3.0 make the world better Speaker: Vadim Krutov, COO at Bitfury Group
Bitfury Group is the world’s leading full-service blockchain technology company. Since their founding in 2011, Bitfury Group has mined over 600,000 Bitcoins.
Presentation: Owning your identity
Speaker: William Wang, CEO, RNS.ID
RNS ID is a digital identity platform developed to support the application and issuance of sovereignty-backed digital IDs (issued by The Republic of Palau).
Panel discussion: The financial landscape redefined: the transformation and future of crypto exchanges
Moderator: Anton Golub, Founder and President, SwissAssetDAO.
Speakers: Luuk Strijers, CCO, Deribit;
Alex Chehade, General Manager, Binance FZE;
Alvin Hu, Head of Institutional Clients, KuCoin.
Fireside chat: Digital assets in the evolving technological and regulatory landscape
Marcel Kasumovich, Deputy Chief Investment Officer, Coinbase Asset Management
Moderator: Vugar Adigozalov, CMO, BeInCrypto
Keynote: Remittance Revolution
Speaker: Jose Lemus, CEO at IBEX
IBEX is a bitcoin infrastructure company specialized in Lightning Network enterprise solutions. Founded in 2018, they are a world leader in providing Lightning-as-a-Service infrastructure for quick, scalable deployment. Company has offices in El Salvador, Guatemala, Mexico, and in the US.
Panel discussion: The rise of digital assets adoption across institutional players
Moderator: Faraj Abutalibov, Venom Foundation, Crypto Executive
Speakers: Sebastian Widmann, Head of Strategy, Komainu;
CJ, Managing Director, Head of Sales (APAC & EMEA), GSR;
Marc Meuwissen, Global Head of Crypto BD, IMC Trading;
Frank van Zegveld, Head of Sales EMEA, Talos Trading.
Panel discussion: How Bitcoin fights monetary colonialism
Moderator: Yue Feng, BITMAIN
Speakers: Jose Lemus, Co-Founder & CEO, IBEX; Vadim Krutov, COO, Bitfury Group;
Anton Golub, Founder and President, SwissAssetDAO.
Presentation: Future of governance and conscious leadership
Speaker: Anastasia Kalinina, CEO, reState Foundation
reState Foundation, a Swiss-based non-profit foundation aiming to reimagine the future of governance and global collaboration.
Anastasia was a Head of Regional Agenda at the World Economic Forum and Senior Advisor on Partnerships to the United Nations Economic Commission for Europe.
Panel discussion: The adoption of digital assets & blockchain from an institutional trading perspective (November 2023)
Moderator: Faraj Abutalibov, Venom Foundation, Crypto Executive
Speakers: Valérie Noël, Head of Trading, Syz Group
Cameron Dickie, Head of Distribution, Laser Digital
William Harvey, Director of Institutional Sales, Bullish
BECOME A PARTNER
We offer our partners to engage with a targeted audience, boost their deal flow, make meaningful connections, meet with senior decision-makers, form new partnerships, and promote their products and services.
Interested in sponsoring Genesis XBT? Please send us an email at sponsors@genesisxbt.com
MEDIA ATTENDANCE
Gain access to cover exclusive announcements, scientific breakthroughs, and in-depth discussions with leading voices in biotechnology, including founders, researchers, executives, and senior decision-makers, as an accredited member of the press.
To apply for media accreditation, please contact us at media@genesisxbt.com